Eli Lilly and Company (NYSE:LLY) Issues Earnings Results, Beats Expectations By $2.32 EPS

Eli Lilly and Company (NYSE:LLY) issued its quarterly earnings data on Wednesday. The company reported $8.38 earnings per share for the quarter, beating analysts’ consensus estimates of $6.06 by $2.32, FiscalAI reports. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.69 billion. During the same quarter last year, the company earned $6.31 earnings per share. The firm’s revenue for the quarter was up 47.7% compared to the same quarter last year. Eli Lilly and Company updated its FY 2026 guidance to 35.500-36.500 EPS.

Here are the key takeaways from Eli Lilly and Company’s conference call:

• Q2 revenue rose 48% year over year to $6.8 billion of incremental growth from key products, led by Mounjaro and Zepbound; non-GAAP EPS increased to $8.38 from $6.31.
• Lilly raised its 2026 outlook, increasing the revenue range to $85 billion-$87 billion and non-GAAP EPS guidance to $35.50-$36.50, reflecting stronger-than-expected first-half performance.
• Foundayo’s launch is gaining traction as access expands through major PBMs and the Medicare GLP-1 Bridge program; Lilly reported recent prescription acceleration, 36,000 U.S. prescribers, and encouraging initial international demand.
• The pipeline produced several important advances, including positive phase III retatrutide results, an FDA submission for orforglipron in diabetes, strong oncology data for pirtobrutinib and selpercatinib, and regulatory progress for weekly insulin efsitora alfa.
• U.S. net pricing declined, with reported price down 3% and an underlying decline of approximately 9% excluding rebate and discount adjustments; management also cautioned that prior-period adjustments and seasonal factors will affect second-half comparisons.

Eli Lilly and Company Stock Up 4.9%

Shares of LLY traded up $54.62 during mid-day trading on Wednesday, hitting $1,170.30. 6,433,137 shares of the company traded hands, compared to its average volume of 2,440,108. The company has a market capitalization of $1.10 trillion, a PE ratio of 41.57, a price-to-earnings-growth ratio of 1.39 and a beta of 0.51. The company has a quick ratio of 1.10, a current ratio of 1.50 and a debt-to-equity ratio of 1.26. The business has a 50 day moving average of $1,156.45 and a 200 day moving average of $1,045.49. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,249.45.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is 24.58%.

Institutional Trading of Eli Lilly and Company

Several large investors have recently bought and sold shares of the stock. State Street Corp increased its stake in Eli Lilly and Company by 1.8% during the 4th quarter. State Street Corp now owns 35,361,916 shares of the company’s stock valued at $38,002,744,000 after purchasing an additional 635,358 shares in the last quarter. Morgan Stanley lifted its stake in shares of Eli Lilly and Company by 2.7% during the fourth quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock worth $16,757,510,000 after buying an additional 407,166 shares during the period. Price T Rowe Associates Inc. MD lifted its stake in shares of Eli Lilly and Company by 10.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,910,505 shares of the company’s stock worth $16,024,022,000 after buying an additional 1,432,069 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Eli Lilly and Company by 1.0% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,499,330 shares of the company’s stock valued at $6,984,700,000 after buying an additional 66,373 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in shares of Eli Lilly and Company by 2.2% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 5,758,206 shares of the company’s stock valued at $6,188,229,000 after buying an additional 125,815 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Strong Q2 beat: Revenue rose 48% year over year to $22.97 billion, surpassing the approximately $20.7 billion consensus estimate. Non-GAAP EPS was $8.38 versus expectations of about $6.06, while reported EPS was $7.94. Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge
• Positive Sentiment: GLP-1 demand drove growth: Mounjaro and Zepbound sales surged, with Mounjaro reportedly up 91% and the two products generating nearly two-thirds of quarterly revenue. Continued volume growth in diabetes and obesity treatments was the primary catalyst for the stock’s advance. Eli Lilly Stock Jumps Over 5% as Mounjaro Sales Surge 91%
• Positive Sentiment: Outlook raised: Lilly increased 2026 revenue guidance to $85 billion-$87 billion from $82 billion-$85 billion and maintained EPS guidance of $35.50-$36.50. The improved outlook indicates management expects momentum to continue. Eli Lilly raises annual revenue forecast as obesity, diabetes drug demand stay strong
• Positive Sentiment: Additional commercial and pipeline support: CVS Health expanded its weight-management program through a Lilly partnership, while Lilly is widening early access to experimental obesity drug retatrutide. The FDA also granted breakthrough therapy designation to investigational cancer drug olomorasib, adding longer-term pipeline potential.
• Neutral Sentiment: Key investor concern: Management indicated that manufacturing capacity could become a bottleneck if GLP-1 demand continues to outpace supply. Lilly is working to expand production, but execution and competition remain important risks at the stock’s elevated valuation.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. JPMorgan Chase & Co. raised their price target on shares of Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a report on Tuesday, July 7th. Barclays boosted their price objective on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research note on Monday, May 4th. UBS Group increased their target price on shares of Eli Lilly and Company from $1,250.00 to $1,425.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Guggenheim raised their target price on shares of Eli Lilly and Company from $1,235.00 to $1,273.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Finally, Citigroup lifted their price target on shares of Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $1,283.64.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.